1. Home
  2. AACG vs BNR Comparison

AACG vs BNR Comparison

Compare AACG & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATA Creativity Global

AACG

ATA Creativity Global

N/A

Current Price

$0.86

Market Cap

41.5M

Sector

Real Estate

ML Signal

N/A

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$11.67

Market Cap

126.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AACG
BNR
Founded
1999
2014
Country
China
China
Employees
N/A
N/A
Industry
Other Consumer Services
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.5M
126.5M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
AACG
BNR
Price
$0.86
$11.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.1K
36.6K
Earning Date
05-15-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$6.79
52 Week High
$2.58
$41.72

Technical Indicators

Market Signals
Indicator
AACG
BNR
Relative Strength Index (RSI) 40.44 57.28
Support Level $0.74 $8.91
Resistance Level $1.07 $12.89
Average True Range (ATR) 0.06 1.21
MACD -0.01 0.23
Stochastic Oscillator 0.00 60.02

Price Performance

Historical Comparison
AACG
BNR

About AACG ATA Creativity Global

ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: